Amneal Pharmaceuticals Completes Acquisition of Liquid Form Generic Pharmaceuticals Manufacturing Plant
Posted on: Thursday, 3 January 2008, 09:00 CST
PATERSON, N.J., Jan. 3 /PRNewswire/ -- Amneal Pharmaceuticals is pleased to announce the completion of its most recent acquisition, a 30,000 sq ft liquid form generic pharmaceuticals manufacturing plant in Branchburg, New Jersey and intellectual property for 18 generic prescription products. This state-of-the-art, cGMP compliant production and R&D facility complements Amneal's existing 40,000 sq ft oral solid pharmaceuticals plant in Paterson, NJ and its new 74,000 sq ft R&D Centre in Gujarat, India to provide a robust offering to the marketplace and enable a strong and diverse pipeline to fuel Amneal's aggressive growth plan.
This new plant, built in 2004 and equipped with the latest equipment and technology, has a production capacity of 7 million bottles per year of Rx liquids as well as over 1 billion tablets/capsules per year of oral solids. The ideally outfitted R&D lab provides the tools and technology necessary for Amneal's superb scientific team to file 10-12 liquid and/or niche oral solid ANDAs to the US FDA annually. As of December 5, 2007 Amneal's Regulatory, R&D, Quality Assurance and Manufacturing management teams have been implementing its methods and standards to bring the operation to Amneal's high levels.
Of the 18 products acquired, one is approved, five have been submitted to the FDA with approvals anticipated in second quarter 2008 while 12 products are in the development pipeline to be filed in 2008-09. The first Amneal products from this plant will begin shipping in February and will be distributed through Amneal's sales and distribution teams via wholesalers and distributors as well as directly to customers.
"This addition of an outstanding generic liquid pharmaceuticals manufacturing plant advances Amneal's strategic plan and enables us to provide a broader offering to our customers. It nicely complements our oral solid capabilities as well as our ophthalmic category joint venture," said Chirag Patel, Amneal's president. The company has been on a steady and rapid expansion mode during 2007 and will continue the same aggressive pace over the next several years.
Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufacturers and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.
Amneal Pharmaceuticals
CONTACT: Jim Luce, Executive Vice President-Sales & Marketing of AmnealPharmaceuticals, LLC, Direct: +1-949-610-8018, Mobile: +1-949-633-2293, Fax:+1-949-610-8218, jim@amneal.com
Web site: http://www.amneal.com/
Source: PRNewswire
Related Articles
- RetireSafe Salutes Pharmaceutical Research and Manufacturers of America for Its Commitment to Cut Drug Prices and Help Seniors in the Medicare 'Doughnut-Hole'
- Ovation Pharmaceuticals's ATryn BLA Accepted for Review By FDA
- Handbook of Pharmaceutical Additives-Third Edition Describes More Than 5300 Trade Name Products and 4000 Generic Chemicals and Materials
- Research and Markets: Pfizer is Canada's Leading Pharmaceutical Company and Generic Manufacturer; Apotex is the Country's Leading Generic Company
- U.S. Ex-Im Bank Approves Comprehensive Guarantee for UPS Capital Loan of $9.38 Million to Fund Establishment of Xechem Pharmaceutical Plant in Nigeria
- Research and Markets: Find Out the Latest Financial Results of Merck Generics - the Major International Generic Manufacturer
- Hi-Tech Pharmaceuticals, Inc. To File Preliminary Injunction Against FDA Seizure of Dietary Supplements Containing Ephedrine Alkaloids
- ProMetic Product Used in the Manufacture of an FDA-Approved Biotherapeutic
- AmerisourceBergen to Purchase All Branded and Generic Pharmaceuticals Only From Manufacturers
- Forest Laboratories Nearing Drug Settlement With Generic Manufacturer
 |
 |
User Comments (0)
RSS Feeds